Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000657241 | SCV000778969 | pathogenic | not provided | 2022-09-28 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 26509978, 21354044, 31776437, 18546366) |
Labcorp Genetics |
RCV000809527 | SCV000949680 | pathogenic | Neurofibromatosis, type 1 | 2024-10-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Val341Cysfs*12) in the NF1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with a clinical diagnosis or suspicion of neurofibromatosis type 1 (PMID: 18546366). ClinVar contains an entry for this variant (Variation ID: 545745). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Genome Diagnostics Laboratory, |
RCV000809527 | SCV001479244 | pathogenic | Neurofibromatosis, type 1 | 2020-10-26 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000809527 | SCV002561622 | pathogenic | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002507143 | SCV002811706 | pathogenic | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2024-02-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003459556 | SCV004199005 | pathogenic | Juvenile myelomonocytic leukemia | 2021-12-02 | criteria provided, single submitter | clinical testing | |
Al Jalila Children’s Genomics Center, |
RCV004798851 | SCV005420491 | pathogenic | Café-au-lait macules with pulmonary stenosis | 2024-10-04 | criteria provided, single submitter | research | PVS1,PS4mod,PM2 |